Mandate

Vinge advises Ampersand Capital Partners

April 22, 2016

Vinge advises Ampersand Capital Partners, a Boston based private equity firm, in connection with the forming of the Gyros Protein Technologies group. The new group consists of Ampersand’s portfolio company Protein Technologies, Inc., a US based provider of peptide synthesis instrumentation and reagents, and the Swedish Gyros group operating within automated nanoliter-scale immunoassays, who’s majority owner is the Swedish Sixth National Pension Fund.
 
Vinge’s team consisted of, among others, the partner in charge Christina Kokko and Kristina Ekberg, Oscar Rydén and Maria Schultzberg.

Related

Vinge advises Bridgepoint in its acquisition of Safe Life

Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.
June 16, 2025

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.
June 16, 2025

Vinge advises Karl Hedin and minority owners on the sale of Toftani Metsanduse OÜ to OÜ Metsavennaskond

Vinge has advised Karl Hedin and the minority owners in connection with the sale of Toftani Metsanduse OÜ to OÜ Metsavennaskond.
June 13, 2025